Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05152953 · ClinicalTrials.gov registry record
Preparing for Pharmacy-based Delivery of Long-acting Injectable Antiretroviral Therapy (LAI-ART)
A clinical trial of HIV, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 63
- Enrollment target
- 4
- Study locations
NCT05152953 is a study of HIV that has completed, run by University of California, San Francisco. The registered enrollment target is 63 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (86% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT05152953, a study of HIV, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 63 participants
- Enrollment target
- 4
- Study locations
Study Summary
BACKGROUND: Long-acting injectable antiretroviral therapy (LAI-ART) is poised to revolutionize HIV treatment and prevention. Community pharmacies could serve as another place for people with HIV to get their ART injections. However, pharmacist and healthcare practitioner attitudes towards pharmacist administration of LAI-ART are understudied. Financial and human resources, pharmacist training, or changes in workflow have not been outlined. Little is known about whether patients will accept ART injections given in pharmacies. OBJECTIVE: The purpose of this project is to address the above knowledge gaps. The information generated can assist in the development of tools that can help scale community pharmacy-based delivery of LAI-ART. METHODS: Using a mixed-methods approach to better understand the pre-implementation environment, the study will employ electronic surveys and will administer semi-structured interviews via telephone for three key stakeholder groups: HIV clinic staff members, community pharmacists, and persons with HIV. Surveys will assess the appropriateness, acceptability, and feasibility of LAI-ART administration in community pharmacies. A semi-structured interview guide has been developed using constructs from the Consolidated Framework for Implementation Research (CFIR). Comparisons between and across stakeholder groups will be performed, looking for common themes as well as discrepancies.
Conditions Studied
Study Locations (4)
Alabama
- Auburn University Harrison School of Pharmacy - Auburn
California
- University of California San Francisco School of Pharmacy - San Francisco
Florida
- Nova Southeastern University College of Pharmacy - Fort Lauderdale
Texas
- Texas A&M Irma Lerma Rangel College of Pharmacy - Kingsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2022-06-08 |
| Est. Completion | 2023-11-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05152953
The ClinicalTrials.gov registry entry for NCT05152953 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 303 other HIV trials with a reported enrollment target (86% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 0 interventions.
NCT05152953 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Alabama, California, Florida.
Frequently Asked Questions
What is clinical trial NCT05152953 about?
NCT05152953 is a clinical study titled "Preparing for Pharmacy-based Delivery of Long-acting Injectable Antiretroviral Therapy (LAI-ART)". BACKGROUND: Long-acting injectable antiretroviral therapy (LAI-ART) is poised to revolutionize HIV treatment and prevention. Community pharmacies could serve as another place for people with HIV to get their ART injections. However, pharmacist and healthcare practitioner attitudes towards pharmacist...
What is the current status of trial NCT05152953?
This trial is currently completed. The enrollment target is 63 participants. The study started on 2022-06-08. Estimated completion is 2023-11-15.
What conditions does trial NCT05152953 study?
This clinical trial studies the following conditions: HIV.
Who is sponsoring clinical trial NCT05152953?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05152953 being conducted?
This trial has 4 study locations across Alabama, California, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Transitional Housing and HIV Health
RECRUITING
-
Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health
RECRUITING · Phase 1
-
Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-1 Research Participants
RECRUITING
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
RECRUITING · Phase 2
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
1MoreStep: An Intervention to Increase HIV Care Engagement and Reduce Intimate Partner Violence Among Black Women Living With HIV
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.